Rexahn Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch REXN and buy or sell other stocks, ETFs, and their options commission-free!About REXN
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders.
CEOGeorge Magrath, III, MD
CEOGeorge Magrath, III, MD
Employees18
Employees18
HeadquartersDurham, North Carolina
HeadquartersDurham, North Carolina
Founded2018
Founded2018
Employees18
Employees18
REXN Key Statistics
Market cap166.52M
Market cap166.52M
Price-Earnings ratio-2.66
Price-Earnings ratio-2.66
Dividend yield—
Dividend yield—
Average volume937.79K
Average volume937.79K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.59
52 Week high$4.59
52 Week low$0.65
52 Week low$0.65
Stock Snapshot
The current Rexahn Pharmaceuticals(REXN) stock price is $2.58, with a market capitalization of 166.52M. The stock trades at a price-to-earnings (P/E) ratio of -2.66.
Rexahn Pharmaceuticals(REXN) stock opened on 2026-03-05 at —. The price climbed to — and dipped to —.
Rexahn Pharmaceuticals(REXN) shares are trading with a volume of 0, against a daily average of 937.79K.
In the last year, Rexahn Pharmaceuticals(REXN) shares hit a 52-week high of $4.59 and a 52-week low of $0.65.
In the last year, Rexahn Pharmaceuticals(REXN) shares hit a 52-week high of $4.59 and a 52-week low of $0.65.
People also own
Based on the portfolios of people who own REXN. This list is generated using Robinhood data, and it’s not a recommendation.